Abstract
MUTATIONAL analysis of the tachykinin NK-1 (refs 1–7), NK-2 (ref. 8) and angiotensin AT-1 (refs 9,10) receptors indicates that non-peptide antagonists act through residues located between the seven transmembrane segments, whereas natural peptide agonists bind mainly to residues scattered in the exterior part of the receptor 1–4,7,11–13. The presumed contact points for the prototype NK-1 antagonist CP96,345 cluster on opposing faces of the outer portions of transmembrane helices V and VI (refs 1–5). Here we show that systematic introduction of histidyl residues at this antagonist-binding site in the human NK-1 receptor gradually converts it into a high-affinity metal-ion-binding site without affecting agonist binding. In a double mutant with histidine residues substituted at the top of transmembrane segments V and VI, respectively, Zn2+ inhibits binding of radiolabelled agonist peptide and efficiently blocks phosphoinositol turnover induced by substance P. We propose that Zn2+ and CP96,345 act as ‘allosteric competitive’ antagonists by stabilizing inactive conformations of the mutant and the wild-type receptor respectively. Introduction of metal-ion-binding sites could be used as a general tool in the structural and functional characterization of helix–helix interactions in G-protein-coupled receptors, as well as in other membrane proteins.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gether, U. et al. Nature 362, 345–348 (1993).
Fong, T. M. et al. Nature 362, 350–353 (1993).
Zoffmann, S., Gether, U. & Schwartz, T. W. FEBS Lett. 336, 506–510 (1993).
Fong, T. M. et al. J. biol. Chem. 269, 2728–2732 (1994).
Gether, U., Nilsson, L., Lowe, J. & Schwartz, T. J. biol. Chem. 269, 23959–23964 (1994).
Cascieri, M. A. et al. J. biol. Chem. 269, 6587–6591 (1994).
Fong, T. M., Huang, R. C. & Stader, C. D. J. biol. Chem. 267, 25664–25667 (1992).
Gether, U. et al. Proc. natn. Acad. Sci. U.S.A. 90, 6194–6198 (1993).
Schambye, H. T., Hjorth, S. A., Bergsma, D. J., Sathe, G. & Schwartz, T. W. Proc. natn. Acad. Sci. U.S.A. 91, 7046–7050 (1994).
Hjorth, S. A., Schambye, H. T., Greenlee, W. J. & Schwartz, T. W. J. biol. Chem. 269, 30953–30959 (1994).
Rosenkilde, M. M., Cahir, M., Gether, U., Hjorth, S. A. & Schwartz, T. W. J. biol. Chem. 269, 28160–28164 (1994).
Schwartz, T. W. Curr. Opin. Biotech. 5, 434–444 (1994).
Huang, R. C., Yu, H., Strader, C. D. & Fong, T. M. Biochemistry 33, 3007–3013 (1994).
Gether, U. et al. Molec. Pharmac. 45, 500–508 (1994).
Glusker, J. P. Adv. Protein Chem. 42, 3–76 (1991).
Chakrabarti, P. Protein Engng 4, 57–63 (1990).
Jerigan, R., Raghunathan, G. & Bahar, I. Curr. Opin. struct. Biol. 4, 256–263 (1994).
Regan, L. A. Rev. Biophys. biomolec. Struct. 22, 257–281 (1993).
Handel, T. M., Williams, S. A. & DeGrado, W. F. Science 261, 879–885 (1993).
Betz, S. F., Raleigh, D. P. & DeGrado, W. F. Curr. Opin. struct. Biol. 3, 601–610 (1993).
Lefkowitz, R., Cotecchia, S., Samama, P. & Costa, T. Trends pharmac. Sci. 14, 303–307 (1993).
Chidac, P., Hebert, T. E., Valiquette, M., Dennis, M. & Bouvier, M. Molec. Pharmac. 45, 490–499 (1994).
Samama, P., Pei, G., Costa, T., Cotecchia, S. & Lefkowitz, R. J. Molec. Pharmac. 45, 390–394 (1993).
Schertler, G. F., Villa, C. & Henderson, R. Nature 362, 770–772 (1993).
Baldwin, J. M. EMBO J. 12, 1693–1703 (1993).
Suryanarayana, S., von Zastrow, M. & Kobilka, B. K. J. biol. Chem. 267, 21991–21994 (1992).
Zhou, W. et al. Molec. Pharmac. 45, 165–170 (1994).
Stappert, J., Wirsching, J. & Kemler, R. Nucleic Acids Res. 20, 624–625 (1992).
Johansen, T. E., Schøller, M., Tolstrhoy, S. & Schwartz, T. W. FEBS Lett. 267, 289–294 (1990).
Gether, U., Johansen, T. E. & Schwartz, T. W. J. biol. Chem. 268, 7893–7898 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elling, C., Nielsen, S. & Schwartz, T. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor. Nature 374, 74–77 (1995). https://doi.org/10.1038/374074a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/374074a0
This article is cited by
-
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
Nature Communications (2019)
-
Endocytosis of G Protein-Coupled Receptors and Their Ligands: Is There a Role in Metal Trafficking?
Cell Biochemistry and Biophysics (2018)
-
Proton-sensing G-protein-coupled receptors
Nature (2003)
-
Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997
British Journal of Pharmacology (1998)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.